To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, single-center, crossover, one-way, drug-interaction study to
evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a
single 400-mg dose of pacritinib in healthy male and female subjects.